1 / 38

Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide

Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide. Mary Ross Southworth, PharmD Safety Evaluator, Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research, FDA. Purpose of Review.

arcelia
Download Presentation

Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide Mary Ross Southworth, PharmD Safety Evaluator, Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research, FDA

  2. Purpose of Review • MT-100: metoclopramide 16 mg/naproxen 500mg • Acute migraine treatment • Proposed dosing chronic, but intermittent manner • Episodic • No more than 6 tablets/month • Risks associated with this type of dosing?

  3. Background • Metoclopramide well known to cause movement disorders • Product labeling • Extrapyramidal symptoms occur in 1 of 500 patients receiving 30 to 40 mg daily • Parkinsonian symptoms occur after prolonged use and are usually reversible • Tardive dyskinesia most common with prolonged use, but can occur with shorter durations of therapy • Neuroleptic Malignant Syndrome occurs rarely • Recommended Daily Dose: 5 to 20 mg QID • Duration of Therapy should not exceed 12 weeks

  4. Total Number of Prescriptions Dispensed (in thousands) in Retail Pharmacies Nationwide for Metoclopramide Products, IMS Health, NPA Plus™, 1995-2004 Source:1995-1996 IMS Health, National Prescription Audit Plus™ book data- Dec 1996, USC 01200-333901997-1999 IMS NPA CD-ROM Dataview Analyzer Total Market CD-ROM Years 2000-2004, extracted February 2005

  5. Points to consider • Reversibility of reaction • Association with dose/duration of therapy • Relationship to proposed dosing of MT-100 • Potential for chronic continuous/intermittent use • Associated Risk factors • Concomitant Drugs • Other patient specific factors

  6. Purpose of Review • Characterize cases of specific adverse events reported in the Adverse Event Reporting System (AERS) database associated with metoclopramide

  7. AERS database • Computerized database containing reports of adverse events • >3 million reports • “Spontaneous” reporting • Not required of health care providers • Sponsors required to report any adverse event of which they become aware • Source of reports • Drug manufacturers/sponsors • Health care providers • Lay people (consumers, patients, patients’ families, lawyers)

  8. Neuroleptic Malignant Syndrome (NMS) Acute dystonia Akathisia Parkinsonism Tardive dyskinesia Number of case reports Daily dose Duration of treatment Risk Factors Reversibility Adverse Events

  9. Search Strategy/Results • Search run using each movement disorder as a search term + “metoclopramide” • Cases classified according to diagnosis made in the case • Points • Case misclassification (tardive vs. acute) • Chronic/intermittent vs. Chronic/continuous • Underreporting due to drug label • Drug has been on the market for a long time • Quality of reports • Status of recovery • Time to recovery

  10. Search Strategy/Results

  11. Description of case series • Demographics • Clinical characteristics • Recovery • Review cases with continuing symptoms • Representative cases • Focus on short term therapy

  12. Neuroleptic Malignant Syndrome (37 cases)

  13. Neuroleptic Malignant Syndrome (37 cases) • Concomitant medications associated with development of NMS or NMS-like symptoms reported in 20 cases • Antidepressants (3) • Antiemetics (8) • Antipsychotics (9) • Drug therapy was used to treat the AE in 18 cases • Dantrolene (12) • Diphenhydramine (5) • Bromocriptine (6) • Symptoms were reported as improved or resolved in 11 cases (NR in 17 cases) • Symptoms reported as continuing in 1 case (dystonic jaw clenching) • Eight patients died NR= not reported

  14. Neuroleptic Malignant Syndrome: Deaths (n=8) • Daily dose • 10 mg to 40 mg (NR in 3 cases) • Mean: 32 mg; Median: 40 mg • PO dosing in 2 cases; IV dosing in 3 cases (NR in 3 cases) • Duration of therapy • 2 days (2); 5 days; 7 days; 8 days; 15 days (NR in two cases) NR= not reported

  15. Acute Dystonia (203 cases)

  16. Acute Dystonia (203 cases) • Concomitant medications associated with development of movement disorders reported in 64 cases • Antidepressants (16) • Antiemetics (27) • Drug therapy was used to treat the AE in 115 cases • Diphenhydramine/anticholinergic (90) • Benztropine (14) • Anxiolytic (16) • Symptoms were reported as improved or resolved in 115 cases • Symptoms were reported as continuing in 12 cases (6%)

  17. Acute Dystonia: Continuing Symptoms (n-12) • Daily dose • 10 mg to 40 mg (NR in 425 cases) • Mean: 25 mg; Median: 20 mg • Oral dosing in 10 cases; Combination IV/PO dosing in 1 case (NR in 1 case) • Duration of therapy • 1 day (1 dose) to 2065 days • Mean: 373 days; Median: 2.5 days

  18. Akathisia (57 cases)

  19. Akathisia (57 cases) • Concomitant medications associated with development of movement disorders reported in 23 cases • Antidepressants (7) • Antiemetics (6) • Antipsychotics (6) • Drug therapy was used to treat the AE in 29 cases • Diphenhydramine/anticholinergic (16) • Benztropine (8) • Anxiolytic (14) • Symptoms were reported as improved or resolved in 31 cases • Symptoms were reported as continuing in 9 cases (16%)

  20. Akathisia: Continuing symptoms (n=9) • Daily dose • 8.6 mg to 40 mg (NR in 1 case) • Mean: 25 mg; Median: 30 mg • Oral dosing in 8 cases (NR in 1 case) • Duration of therapy • 17 to 2555 days (NR in 1 case) • Mean: 525 days; Median: 119 days

  21. Parkinsonism (35 cases)

  22. Parkinsonism (35 cases) • Concomitant medications associated with development of movement disorders reported in 13 cases • Antidepressants (5) • Antipsychotics (3) • Drug therapy was used to treat the AE in 18 cases • Diphenhydramine/anticholinergic (4) • Amantadine (2) • Antiparkinson Medication (6) • Benztropine (3) • Symptoms were reported as improved or resolved in 15 cases • Symptoms were reported as continuing in 8 cases (23%)

  23. Parkinsonism: Continuing Symptoms (n=8) • Daily dose • 20 mg to 40 mg (NR in 2 cases) • Mean: 32 mg; Median: 30 mg • 7 cases PO dosing (NR in 1 case) • Duration of therapy • 1 day (3 doses) to 203 days (NR in 1 case) • Mean: 80 days; Median: 81 days

  24. Tardive Dyskinesia (67 cases)

  25. Tardive Dyskinesia (67 cases) • Concomitant medications associated with development of movement disorders reported in 25 cases • Antidepressants (14) • Antiemetics (3) • Antipsychotics (4) • Drug therapy was used to treat the AE in 19 cases • Diphenhydramine/anticholinergic (10) • Benztropine (10) • Anxiolytic (10) • Symptoms were reported as improved or resolved in 12 cases • Symptoms were reported as continuing in 20 cases (30%)

  26. Tardive Dyskinesia: Continuing Symptoms (n=20) • Daily dose • 5 mg to 80 mg (NR in 7 cases) • Mean: 53 mg; Median 40 mg • Oral dosing in 15 cases; IV dosing in 1 case; Combination IV/PO in one case (NR in 4 cases) • Duration of therapy • 1 day to 4715 days (NR in 5 cases) • Mean: 769 days; Median 165 days

  27. Further analysis • Characteristics of cases reporting continuing symptoms and short term therapy • Cases of TD related to short term therapy

  28. Characteristics of Cases with Continuing Symptoms • 50 cases in review (out of 401) reported continuing symptoms • 8 Parkinsons • 20 TD • 9 Akathisia • 12 acute dystonia • 1 NMS (likely a dystonic reactions) • 27/50 cases with continuing symptoms reported a duration of therapy >30 days • 8 cases did not report duration of therapy

  29. Characteristics of Cases with Continuing Symptoms • 15 cases with continuing symptoms had a duration of therapy of <31 days • 7 of these cases were acute dystonia • 8 cases with continuing symptoms had a duration of therapy of ≤ 3 days • 1 Parkinsonism, 2 TD, 4 Acute dystonia, 1 NMS (likely a dystonic reaction) • Most (6) occurred after at least 3 doses

  30. Representative Case • A 49 year old female received 2 doses of metoclopramide 20 mg PO over 2 days for treatment of gastric reflux. Concomitant therapy included cimetidine. On day 2 of therapy she developed dystonic reactions consisting of torticollis and trismus. Her dystonic reaction was reversed by diphenhydramine. However she subsequently complained of left sided weakness and temporary loosening of the teeth.

  31. Representative Case • A 34 year old female with nausea received metoclopramide 10 mg PO TID for 3 doses and experienced difficulty breathing, extremity shaking, head and neck “jerking back”. She went to the ED where she was treated with benztropine after which she started to relax, however symptoms still occurred. She was subsequently treated with lorazepam and paroxetine, which did not completely relieve the symptoms. She was seen in the ED and by neurologists several times for reactions milder than the first reaction. Approximately 3 months later she still suffers from head pain, dizziness, tingling, pressure, fatigue, agitation, involuntary shaking, muscle spasms, and neck pain among other symptoms.

  32. Representative Case • A 27 year old male received 3 doses of metoclopramide 10 mg PO over 2 days for diabetic gastroparesis. He experienced a dystonic reaction with psychotic tendencies, agitation, and agitation with suicidal tendencies on the second day of therapy. He was treated in the ED with diphenhydramine and lorazepam. Once discharged, he continued to have symptoms of inability to concentrate, slowed mental processing, difficulty focusing, eye strain, vertigo, loss of equilibrium, fatigue, dizziness, and hallucinations

  33. Cases of Tardive Dyskinesia associated with Duration of therapy <30 days • Concern about risk to “chronic over-users” of migraine therapy • Tardive dyskinesia can be a long term/permanent adverse event • 25th percentile of duration of therapy 29.5 days

  34. Distribution of TD cases based on duration of therapy (n=67) Duration of Therapy (days)

  35. Cases of Tardive Dyskinesia associated with Duration of therapy <30 days • 15 cases of TD reported a duration of therapy <31 days • Status of recovery not reported in 9 cases • Symptoms reported as resolved in 1 case • Continuing symptoms were reported in 5 cases • 2/5 cases reported symptoms as improved • 2/5 cases reported IV dosing • 4/5 cases reported daily doses of 40 mg • Unable to distinguish “chronic/intermittent” vs “chronic/continuous”

  36. Dosing characteristics • Cases of movement disorders associated with intermittent dosing not discriminated in AERS • Intermittent dosing not clearly described in the reports • Not commonly used • Not reported • Few movement disorder related adverse events

  37. Conclusions • Most reports with continuing symptoms of the adverse event involved long term therapy (>30 days) • Intermittent vs. continuous • Eight cases in which very short term therapy (≤ 3 days) led to continuing symptoms • Five cases of TD associated with therapy <31 days reported continuing symptoms • Concomitant medications associated with movement disorders frequently present in the cases • 2/8 deaths from NMS occurred after <3 days of therapy

  38. Acknowledgements • Cindy Kortepeter, PharmD • Kate Phelan, RPh • Mark Avigan, MD CM • Sigal Kaplan, PhD, BS Pharm • Judy Staffa, MPH, RPh

More Related